Trending News Today: Cancer Drug Costs Should Align with Value, Panel Says

FDA Commissioner Scott Gottlieb, MD, has become a key leader in the fight against high drug costs, according to The Hill. Dr Gottlieb previously said the FDA must take action against brand name manufacturers that have been blocking generic products from emerging in an effort to reduce competition. President Donald Trump addressed the issue of drug costs during his campaign and has delegated efforts to Dr Gottlieb, who is facing the problem head-on, according to the article.

Yesterday, the House voted down the controversial “right to try” bill, which would allow patients to access investigational treatments, according to Politico. The vote, which fell short of the two-thirds majority, may be a setback for President Trump, who voiced support for the bill. Opposing Democrats questioned whether the legislation would actually help patients, while also noting that the GOP did not bring the bill to a committee before the vote, according to the article.

A White House panel yesterday suggested several steps to control the rising cost of cancer treatments, according to STAT. Notably, the panel recommended that value should be determined for costly cancer medications, as they concluded price and value are currently misaligned, according to the article. By aligning price and value, the panel said that patients would receive better care and manufacturers would have incentive to develop more effective drugs, STAT reported.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

Nilotinib (Tasigna) was previously granted priority review for the treatment of pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Daily doses of sildenafil (Viagra) cut the development of polyps by 50% in mouse models.
Black patients may be eligible for a shorter course of hepatitis C virus treatment.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.